ZA201907755B - 5-5 fused rings as c5a inhibitors - Google Patents

5-5 fused rings as c5a inhibitors

Info

Publication number
ZA201907755B
ZA201907755B ZA2019/07755A ZA201907755A ZA201907755B ZA 201907755 B ZA201907755 B ZA 201907755B ZA 2019/07755 A ZA2019/07755 A ZA 2019/07755A ZA 201907755 A ZA201907755 A ZA 201907755A ZA 201907755 B ZA201907755 B ZA 201907755B
Authority
ZA
South Africa
Prior art keywords
inhibitors
fused rings
fused
rings
Prior art date
Application number
ZA2019/07755A
Other languages
English (en)
Inventor
Pingchen Fan
Christopher W Lange
Rebecca M Lui
Viengkham Malathong
Venkat Reddy Mali
Sreenivas Punna
Yibin Zeng
Penglie Zhang
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of ZA201907755B publication Critical patent/ZA201907755B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Liquid Crystal Substances (AREA)
  • Glass Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Insulating Materials (AREA)
ZA2019/07755A 2017-05-31 2019-11-22 5-5 fused rings as c5a inhibitors ZA201907755B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762513025P 2017-05-31 2017-05-31
PCT/US2018/034908 WO2018222601A1 (en) 2017-05-31 2018-05-29 5-5 FUSED RINGS AS C5a INHIBITORS

Publications (1)

Publication Number Publication Date
ZA201907755B true ZA201907755B (en) 2023-05-31

Family

ID=64455572

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2019/07755A ZA201907755B (en) 2017-05-31 2019-11-22 5-5 fused rings as c5a inhibitors

Country Status (16)

Country Link
US (2) US10683294B2 (enExample)
EP (1) EP3630774B1 (enExample)
JP (1) JP7141129B2 (enExample)
KR (1) KR102586710B1 (enExample)
CN (1) CN111032658B (enExample)
AR (1) AR111841A1 (enExample)
AU (1) AU2018277523B2 (enExample)
CA (1) CA3064025A1 (enExample)
ES (1) ES2934507T3 (enExample)
IL (1) IL270842B2 (enExample)
MA (1) MA48800A (enExample)
MX (1) MX391392B (enExample)
NZ (1) NZ759295A (enExample)
TW (1) TWI813570B (enExample)
WO (1) WO2018222601A1 (enExample)
ZA (1) ZA201907755B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102638253B1 (ko) 2017-05-31 2024-02-16 케모센트릭스, 인크. C5a 억제제로서의 6-5 융합 고리
JP7141129B2 (ja) 2017-05-31 2022-09-22 ケモセントリックス,インコーポレイティド C5a阻害剤としての5-5融合環
MA51327A (fr) 2017-12-22 2021-05-26 Chemocentryx Inc Composés cycliques fusionnés en 5,5 à substitution diaryle, utilisés en tant qu'inhibiteurs du c5ar
MX2020006459A (es) 2017-12-22 2020-11-06 Chemocentryx Inc Compuestos de anillos fusionados 6,5 diaril sustituidos como inhibidores de c5ar.
ES2993034T3 (en) * 2018-04-02 2024-12-20 Chemocentryx Inc Prodrugs of fused-bicyclic c5ar antagonists
KR102890201B1 (ko) 2019-07-10 2025-11-24 케모센트릭스, 인크. Pd-l1 억제제로서의 인단
CN112300169B (zh) * 2019-07-26 2022-03-04 上海美迪西生物医药股份有限公司 吡咯并吡唑类衍生物、其制备方法及其在医药上的应用
ES3068390T3 (en) 2019-10-16 2026-05-29 Chemocentryx Inc Heteroaryl-biphenyl amides for the treatment of pd-l1 diseases
AU2020368392B2 (en) 2019-10-16 2026-01-08 Chemocentryx, Inc. Heteroaryl-biphenyl amines for the treatment of PD-L1 diseases
US12668593B2 (en) 2020-09-28 2026-06-30 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Pyrazole compound and preparation method therefor and use thereof
CA3192880A1 (en) 2020-10-28 2022-05-05 Chemocentryx, Inc. Methods of treating hidradenitis suppurativa

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2416527C (en) 2000-08-10 2009-12-22 Pharmacia Italia S.P.A. Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
AU7622500A (en) 2000-09-29 2002-07-01 Neurogen Corp High affinity small molecule c5a receptor modulators
SE524438C2 (sv) 2000-10-05 2004-08-10 Magnus Georg Goertz Fjärrstyrt dörrelaterat låsarrangemang, första och andra datorpogramprodukt, bärande medium och ett datorlösbart medium
US7902179B2 (en) 2001-04-26 2011-03-08 Ajinomoto Co., Inc. Heterocyclic compounds
ITMI20012025A1 (it) 2001-09-28 2003-03-28 Dompe Spa Sali di ammonio quaternari di omega-amminoalchilammidi di acidi r 2-aril-propionici e composizioni farmaceutiche che li contengono
WO2003082828A1 (en) 2002-03-28 2003-10-09 Neurogen Corporation Substituted tetrahydroisoquinolines as c5a receptor modulators
CA2479928A1 (en) 2002-03-28 2003-10-09 Neurogen Corporation Substituted biaryl amides as c5a receptor modulators
WO2003084524A1 (en) 2002-03-29 2003-10-16 Neurogen Corporation Combination therapy for the treatment of conditions with pathogenic inflammatory components
WO2004016592A1 (en) 2002-08-14 2004-02-26 Ppd Discovery, Inc. Prenylation inhibitors and methods of their synthesis and use
US7169775B2 (en) 2002-08-21 2007-01-30 Neurogen Corporation Amino methyl imidazoles as C5a receptor modulators
AU2003291403A1 (en) 2002-11-08 2004-06-03 Neurogen Corporation 3-substituted-6-aryl pyridined as ligands of c5a receptors
US20040214856A1 (en) 2003-04-23 2004-10-28 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
AU2003902354A0 (en) 2003-05-15 2003-05-29 Harkin, Denis W. Treatment of haemorrhagic shock
US20060154917A1 (en) 2003-07-03 2006-07-13 Neurogen Corporation Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators
WO2006042102A2 (en) * 2004-10-05 2006-04-20 Neurogen Corporation Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds
US7598255B2 (en) 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
US20070112015A1 (en) 2005-10-28 2007-05-17 Chemocentryx, Inc. Substituted dihydropyridines and methods of use
PE20110063A1 (es) 2008-06-20 2011-02-16 Genentech Inc DERIVADOS DE [1, 2, 4]TRIAZOLO[1, 5-a]PIRIDINA COMO INHIBIDORES DE JAK
JP5819730B2 (ja) 2008-12-22 2015-11-24 ケモセントリックス,インコーポレイティド C5aRアンタゴニスト
US20110275639A1 (en) 2008-12-22 2011-11-10 Chemocentryx, Inc. C5aR ANTAGONISTS
DK2585064T3 (en) 2010-06-24 2017-07-24 Chemocentryx Inc C5aR antagonists
US8846656B2 (en) 2011-07-22 2014-09-30 Novartis Ag Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators
PE20151139A1 (es) 2012-08-16 2015-08-07 Janssen Pharmaceutica Nv Pirrolopirazoles como bloqueadores del canal de calcio tipo n
CN103421006B (zh) 2013-08-18 2016-06-22 上海师范大学 2,3,5,7-四取代二氢吡唑并六氢吡啶衍生物及其制备方法和应用
GB201321746D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
SG11201808625QA (en) 2016-04-04 2018-10-30 Chemocentryx Inc SOLUBLE C5aR ANTAGONISTS
KR102638253B1 (ko) 2017-05-31 2024-02-16 케모센트릭스, 인크. C5a 억제제로서의 6-5 융합 고리
JP7141129B2 (ja) 2017-05-31 2022-09-22 ケモセントリックス,インコーポレイティド C5a阻害剤としての5-5融合環
MX2020006459A (es) 2017-12-22 2020-11-06 Chemocentryx Inc Compuestos de anillos fusionados 6,5 diaril sustituidos como inhibidores de c5ar.
MA51327A (fr) 2017-12-22 2021-05-26 Chemocentryx Inc Composés cycliques fusionnés en 5,5 à substitution diaryle, utilisés en tant qu'inhibiteurs du c5ar
ES2993034T3 (en) 2018-04-02 2024-12-20 Chemocentryx Inc Prodrugs of fused-bicyclic c5ar antagonists

Also Published As

Publication number Publication date
RU2019142985A (ru) 2021-06-30
MX2019014292A (es) 2022-04-07
JP2020522483A (ja) 2020-07-30
US10683294B2 (en) 2020-06-16
US20180346471A1 (en) 2018-12-06
MA48800A (fr) 2020-04-08
WO2018222601A1 (en) 2018-12-06
CN111032658B (zh) 2022-12-20
IL270842B2 (en) 2023-05-01
NZ759295A (en) 2026-03-27
RU2019142985A3 (enExample) 2021-09-03
EP3630774A4 (en) 2020-10-07
TWI813570B (zh) 2023-09-01
ES2934507T3 (es) 2023-02-22
KR20200013720A (ko) 2020-02-07
US20210009594A1 (en) 2021-01-14
IL270842A (en) 2020-01-30
JP7141129B2 (ja) 2022-09-22
AU2018277523B2 (en) 2022-06-23
AU2018277523A1 (en) 2019-12-05
KR102586710B1 (ko) 2023-10-10
AR111841A1 (es) 2019-08-21
EP3630774A1 (en) 2020-04-08
TW201902897A (zh) 2019-01-16
MX391392B (es) 2025-03-21
CN111032658A (zh) 2020-04-17
BR112019025230A2 (pt) 2020-06-16
IL270842B1 (en) 2023-01-01
EP3630774B1 (en) 2022-11-23
US11479553B2 (en) 2022-10-25
CA3064025A1 (en) 2018-12-06

Similar Documents

Publication Publication Date Title
IL270828A (en) 6-5 fused ring as C5a inhibitors
ZA201905618B (en) Fused imidazo-piperidine jak inhibitors
IL270842A (en) 6-5 fused ring as C5a inhibitors
IL249261B (en) Implications of a compressed dihydropyrimido ring as an hbv inhibitor
PT3601283T (pt) Composto inibidor de jak de imidazo-piperidina fundido
AU365267S (en) Ring
TWD174459S (zh) 戒指
TWD174457S (zh) 戒指
PL3279187T3 (pl) Pochodna z 9-członowym skondensowanym pierścieniem
IL269409A (en) Combinations of chk1- and wee1 - inhibitors
PL3289248T3 (pl) Pierścienie uszczelniające
SG11201706941WA (en) Improved metal seal ring
GB201603056D0 (en) Ring clip
GB201512682D0 (en) Joint stabilisation
IL253322A0 (en) bace1 inhibitors
IL274496A (en) macro carrier
SG10202003176WA (en) Ring assembly
SI3243016T1 (sl) Tesnilni obroč
GB201712932D0 (en) No title
PL3311060T3 (pl) Nośnik rury
GB201619513D0 (en) 2-par clamp ring method
AU201812909S (en) Ring
GB201720326D0 (en) Nimb Ring
AU201715227S (en) Ring
AU201715228S (en) Ring